461 related articles for article (PubMed ID: 29736724)
21. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
22. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
23. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.
Mazzocchi AR; Rajan SAP; Votanopoulos KI; Hall AR; Skardal A
Sci Rep; 2018 Feb; 8(1):2886. PubMed ID: 29440675
[TBL] [Abstract][Full Text] [Related]
24. What role could organoids play in the personalization of cancer treatment?
Francies HE; Garnett MJ
Pharmacogenomics; 2015; 16(14):1523-6. PubMed ID: 26485224
[TBL] [Abstract][Full Text] [Related]
25. Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models.
Tiriac H; French R; Lowy AM
J Vis Exp; 2020 Jan; (155):. PubMed ID: 32009658
[TBL] [Abstract][Full Text] [Related]
26. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
Struzyna LA; Watt ML
Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
[TBL] [Abstract][Full Text] [Related]
27. Drug discovery through stem cell-based organoid models.
Ranga A; Gjorevski N; Lutolf MP
Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
[TBL] [Abstract][Full Text] [Related]
28. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
29. An Organoid-Based Preclinical Model of Human Gastric Cancer.
Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
[TBL] [Abstract][Full Text] [Related]
30. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
31. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity.
Jung DJ; Shin TH; Kim M; Sung CO; Jang SJ; Jeong GS
Lab Chip; 2019 Sep; 19(17):2854-2865. PubMed ID: 31367720
[TBL] [Abstract][Full Text] [Related]
32. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening.
Deben C; De La Hoz EC; Compte ML; Van Schil P; Hendriks JMH; Lauwers P; Yogeswaran SK; Lardon F; Pauwels P; Van Laere S; Bogaerts A; Smits E; Vanlanduit S; Lin A
Cell Oncol (Dordr); 2023 Apr; 46(2):299-314. PubMed ID: 36508089
[TBL] [Abstract][Full Text] [Related]
33. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Zhang Y; Houchen CW; Li M
Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
[TBL] [Abstract][Full Text] [Related]
34. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
Costamagna G; Comi GP; Corti S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
[TBL] [Abstract][Full Text] [Related]
35. Organoid development in cancer genome discovery.
Gao D; Chen Y
Curr Opin Genet Dev; 2015 Feb; 30():42-8. PubMed ID: 25796043
[TBL] [Abstract][Full Text] [Related]
36. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
[TBL] [Abstract][Full Text] [Related]
37. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
Kim S; Choung S; Sun RX; Ung N; Hashemi N; Fong EJ; Lau R; Spiller E; Gasho J; Foo J; Mumenthaler SM
SLAS Discov; 2020 Aug; 25(7):744-754. PubMed ID: 32349587
[TBL] [Abstract][Full Text] [Related]
39. On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.
Sailer V; Pauli C; Merzier EC; Mosquera JM; Beltran H; Rubin MA; Rao RA
Anticancer Res; 2017 Apr; 37(4):1569-1573. PubMed ID: 28373416
[TBL] [Abstract][Full Text] [Related]
40. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.
Pasch CA; Favreau PF; Yueh AE; Babiarz CP; Gillette AA; Sharick JT; Karim MR; Nickel KP; DeZeeuw AK; Sprackling CM; Emmerich PB; DeStefanis RA; Pitera RT; Payne SN; Korkos DP; Clipson L; Walsh CM; Miller D; Carchman EH; Burkard ME; Lemmon KK; Matkowskyj KA; Newton MA; Ong IM; Bassetti MF; Kimple RJ; Skala MC; Deming DA
Clin Cancer Res; 2019 Sep; 25(17):5376-5387. PubMed ID: 31175091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
